← Back to Search

Local Anesthetic

Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine

Phase 4
Recruiting
Research Sponsored by The Cooper Health System
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
* undergoing robotic wedge resection or lobectomy for lung mass(es)
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 hours post-surgery
Awards & highlights
Drug Has Already Been Approved
No Placebo-Only Group
Pivotal Trial

Summary

This trial is testing two different methods for pain relief after robotic lung surgery. One method uses a newer, long-lasting painkiller. The other method uses a combination of an older painkiller, a medication that helps with pain relief, and a medication that reduces inflammation. The goal is to determine which method provides better pain control.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 hours post-surgery
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 hours post-surgery for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Visual Analogue Scale pain scores

Awards & Highlights

Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Bupivacaine/epinephrine + dexamethasoneExperimental Treatment1 Intervention
Group II: Liposomal bupivacaineActive Control1 Intervention

Find a Location

Who is running the clinical trial?

The Cooper Health SystemLead Sponsor
81 Previous Clinical Trials
35,593 Total Patients Enrolled
~5 spots leftby Dec 2025